Safetyslug.com – SCHOTT Pharma Reaffirms Fiscal 2026 Guidance Amid Ongoing Glass Syringe Challenges
SCHOTT Pharma reported its fiscal second-quarter 2026 earnings on Wednesday, reaffirming its full-year outlook despite continued headwinds from major glass syringe customers and weaker demand in specific drug delivery segments.
The company posted quarterly sales of €247.9 million, slightly above consensus estimates of €246 million. Revenue remained flat on a constant currency basis, compared with analyst expectations of 0.6% growth, while reported sales declined 1.8% year-over-year. High-value solutions accounted for 55% of the company’s total sales mix during the quarter.
Q2 EBITDA Slightly Misses Expectations
SCHOTT Pharma recorded EBITDA of €64.6 million, slightly below consensus expectations of €65 million. This resulted in an EBITDA margin of 26.0%, compared with the market forecast of 26.4%.
While profitability remained solid, margin pressure reflected ongoing product mix challenges and softer utilization rates in certain divisions.
Full-Year Fiscal 2026 Guidance Remains Intact
SCHOTT Pharma maintained its fiscal 2026 revenue growth guidance of approximately 2% to 5% organic growth at constant currency, compared with consensus expectations of 3.3%.
Key growth drivers include:
- Drug Containment Solutions expected to remain the primary sales growth engine
- Drug Delivery Systems facing continued pressure due to revised glass syringe demand from major customers
- Weak polymer syringe demand continuing to weigh on performance
- Lower mRNA-related volumes impacting overall syringe sales
EBITDA Margin Target Holds at Around 27%
The company also reaffirmed its full-year EBITDA margin target of approximately 27%, slightly below consensus expectations of 27.1%.
Margin headwinds include:
- Product mix pressure
- Underutilized Drug Delivery Systems capacity
- Ramp-up costs for new manufacturing plants in Serbia and Hungary
These factors are expected to continue affecting short-term profitability even as SCHOTT Pharma invests for long-term capacity expansion.
High-Value Solutions and Capital Expenditure Outlook
SCHOTT Pharma expects its share of high-value solutions to remain stable at the prior-year level of 57%, underlining the company’s strategic focus on premium pharmaceutical packaging and advanced drug containment technologies.
Fiscal 2026 investment outlook:
- Capital expenditure projected between €140 million and €160 million
This elevated investment level reflects the company’s commitment to expanding production infrastructure and strengthening future growth potential.
Strategic Outlook: Stability Despite Sector Headwinds
Despite ongoing challenges in syringe demand, SCHOTT Pharma’s reaffirmed guidance signals management confidence in its diversified business model and medium-term expansion strategy.
The company’s ability to sustain revenue growth, preserve margins near target levels, and maintain a strong focus on high-value solutions will likely remain key investor priorities as the fiscal year progresses.